{"id":53812,"date":"2026-01-12T22:43:12","date_gmt":"2026-01-12T14:43:12","guid":{"rendered":"https:\/\/flcube.com\/?p=53812"},"modified":"2026-01-12T22:43:22","modified_gmt":"2026-01-12T14:43:22","slug":"insilico-medicine-doses-first-patient-in-phase-iia-study-of-ai-designed-ism5411-for-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53812","title":{"rendered":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced that the first patient has been dosed in the <strong>BETHESDA Phase\u202fIIa trial (NCT07265570)<\/strong> evaluating <strong>ISM5411<\/strong> (generic name: <strong>Garutadustat<\/strong>), a gut\u2011restricted PHD inhibitor developed via its <strong>Pharma.AI<\/strong> generative platform, for the treatment of <strong>ulcerative colitis (UC)<\/strong>, a major form of inflammatory bowel disease (IBD).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>BETHESDA Phase\u202fIIa (NCT07265570)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Multicenter, randomized, double\u2011blind, placebo\u2011controlled<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>~80 ulcerative colitis patients<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety, tolerability, pharmacokinetics (PK)<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Clinical remission\/response, endoscopic improvement, histopathology, biomarkers<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>First patient dosed November\u202f2025<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>Topline data expected Q4\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel PHD (prolyl hydroxylase domain) inhibitor with a unique dual mechanism<\/li>\n\n\n\n<li><strong>Dual Action:<\/strong> Combines <strong>anti\u2011inflammatory activity<\/strong> with <strong>intestinal barrier repair<\/strong>, addressing both immune dysregulation and epithelial integrity in IBD<\/li>\n\n\n\n<li><strong>AI\u2011Driven Design:<\/strong> Discovered and optimized using Insilico\u2019s <strong>Pharma.AI<\/strong> platform, featuring a novel chemical scaffold not found in existing PHD inhibitors<\/li>\n\n\n\n<li><strong>Gut\u2011Restriction:<\/strong> Engineered for minimal systemic absorption, potentially reducing off\u2011target effects (e.g., anemia, cardiovascular risk) seen with systemic JAK or S1P modulators<\/li>\n\n\n\n<li><strong>Phase I Results:<\/strong> Two completed studies in Australia and China demonstrated <strong>favorable safety<\/strong>, <strong>no Grade\u202f\u2265\u202f3 adverse events<\/strong>, and <strong>gut\u2011restricted PK profile<\/strong> with target engagement in colonic tissue<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-i-summary\">Clinical Evidence \u2013 Phase I Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Safety<\/strong><\/td><td>100\u202f% of subjects (n\u202f=\u202f72) completed dosing; no serious adverse events<\/td><\/tr><tr><td><strong>PK Profile<\/strong><\/td><td>Plasma Cmax &lt;\u202f5\u202fng\/mL; fecal concentrations &gt;\u202f1,000\u00d7 higher than plasma<\/td><\/tr><tr><td><strong>PD Marker<\/strong><\/td><td>Colonic HIF\u20111\u03b1 stabilization confirmed in 95\u202f% of biopsy samples<\/td><\/tr><tr><td><strong>GI Tolerability<\/strong><\/td><td>Mild nausea (8\u202f%), no dose\u2011limiting toxicity up to 200\u202fmg BID<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2025E<\/th><th>2026E<\/th><th>2027E<\/th><\/tr><\/thead><tbody><tr><td><strong>China UC Prevalence<\/strong><\/td><td>500,000<\/td><td>520,000<\/td><td>540,000<\/td><\/tr><tr><td><strong>Moderate\u2011to\u2011Severe Cases<\/strong><\/td><td>200,000<\/td><td>208,000<\/td><td>216,000<\/td><\/tr><tr><td><strong>ISM5411 Addressable Population<\/strong><\/td><td>60,000<\/td><td>62,400<\/td><td>64,800<\/td><\/tr><tr><td><strong>Projected Market Share<\/strong><\/td><td>0\u202f%<\/td><td>5\u202f%<\/td><td>12\u202f%<\/td><\/tr><tr><td><strong>Estimated Annual Price<\/strong><\/td><td>\u2013<\/td><td>\u00a565,000<\/td><td>\u00a562,000<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>\u00a5203\u202fmillion<\/td><td>\u00a5482\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China IBD Market Landscape:<\/strong> Oral small\u2011molecule market dominated by <strong>tofacitinib<\/strong> (JAK inhibitor) and emerging <strong>S1P modulators<\/strong>; unmet need for safer, gut\u2011targeted therapies remains high<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> ISM5411\u2019s <strong>gut\u2011restricted design<\/strong> could minimize systemic immunosuppression, offering a safety profile advantage over systemic JAK\/S1P agents<\/li>\n\n\n\n<li><strong>Strategic Partnership Potential:<\/strong> Insilico is in discussions with <strong>regional pharma partners<\/strong> for co\u2011promotion in Southeast Asia and Japan, leveraging PHD inhibition\u2019s novel mechanism<\/li>\n\n\n\n<li><strong>Pipeline Value:<\/strong> Positive Phase\u202fIIa data would validate Pharma.AI\u2019s IBD design capability, supporting Insilico\u2019s broader <strong>IDP (Intestinal Disease Portfolio)<\/strong> including candidates for Crohn\u2019s disease and celiac disease<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical timelines, regulatory pathways, and commercial projections for ISM5411. Actual results may differ due to enrollment rates, competitive dynamics, and evolving treatment paradigms in IBD.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[99,62,4514,164],"class_list":["post-53812","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ai","tag-clinical-trial-approval-initiation","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53812\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53812\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:43:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:43:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease\",\"datePublished\":\"2026-01-12T14:43:12+00:00\",\"dateModified\":\"2026-01-12T14:43:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Clinical trial approval \\\/ initiation\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53812#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53812\",\"name\":\"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:43:12+00:00\",\"dateModified\":\"2026-01-12T14:43:22+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53812\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53812#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53812","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease","og_description":"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).","og_url":"https:\/\/flcube.com\/?p=53812","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:43:12+00:00","article_modified_time":"2026-01-12T14:43:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53812#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53812"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease","datePublished":"2026-01-12T14:43:12+00:00","dateModified":"2026-01-12T14:43:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53812"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Clinical trial approval \/ initiation","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53812#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53812","url":"https:\/\/flcube.com\/?p=53812","name":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:43:12+00:00","dateModified":"2026-01-12T14:43:22+00:00","description":"Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA Phase\u202fIIa trial (NCT07265570) evaluating ISM5411 (generic name: Garutadustat), a gut\u2011restricted PHD inhibitor developed via its Pharma.AI generative platform, for the treatment of ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53812#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53812"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53812#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Doses First Patient in Phase\u202fIIa Study of AI\u2011Designed ISM5411 for Inflammatory Bowel Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53812"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53812\/revisions"}],"predecessor-version":[{"id":53813,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53812\/revisions\/53813"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}